Skip to main content

Sensyne Health Share Forecast, Price & News

GBX 153.50
+1.00 (+0.66 %)
(As of 05/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume217,789 shs
Average Volume320,148 shs
Market Capitalization£252.97 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SENS News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensyne Health and its competitors with MarketBeat's FREE daily newsletter.

Sensyne Health logo

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's ‘Initial Code of Conduct for data-driven health and care technology'.


See More Headlines

Industry, Sector and Symbol

Industry Health Information Services
Phone44 3300 581845
Year FoundedN/A

Sales & Book Value

Annual Sales£3.98 million
Cash FlowGBX 14.49 per share
Book ValueGBX 23.70 per share





Market Cap£252.97 million
Next Earnings DateN/A


Overall MarketRank

1.50 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sensyne Health (LON:SENS) Frequently Asked Questions

Is Sensyne Health a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensyne Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sensyne Health stock.
View analyst ratings for Sensyne Health
or view top-rated stocks.

What stocks does MarketBeat like better than Sensyne Health?

Wall Street analysts have given Sensyne Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sensyne Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Sensyne Health's stock price been impacted by Coronavirus?

Sensyne Health's stock was trading at GBX 39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SENS stock has increased by 293.6% and is now trading at GBX 153.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SENS?

2 analysts have issued 12-month target prices for Sensyne Health's shares. Their forecasts range from GBX 310 to GBX 310. On average, they anticipate Sensyne Health's stock price to reach GBX 310 in the next year. This suggests a possible upside of 102.0% from the stock's current price.
View analysts' price targets for Sensyne Health
or view top-rated stocks among Wall Street analysts.

Who are some of Sensyne Health's key competitors?

What other stocks do shareholders of Sensyne Health own?

What is Sensyne Health's stock symbol?

Sensyne Health trades on the London Stock Exchange (LON) under the ticker symbol "SENS."

How do I buy shares of Sensyne Health?

Shares of SENS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Sensyne Health's stock price today?

One share of SENS stock can currently be purchased for approximately GBX 153.50.

How much money does Sensyne Health make?

Sensyne Health has a market capitalization of £252.97 million and generates £3.98 million in revenue each year.

How many employees does Sensyne Health have?

Sensyne Health employs 70 workers across the globe.

What is Sensyne Health's official website?

The official website for Sensyne Health is

How can I contact Sensyne Health?

The company can be reached via phone at 44 3300 581845.

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.